Rankings / Metabolic Health
Metabolic Health
Glucose, lipids, weight, and liver — the cardiometabolic axis. GLP-1 agonists, statins, PCSK9 inhibitors, Lp(a)-targeted RNA agents, bile acids, MASLD-focused drugs.
| # | Compound | Ev | Bn | Sf | Grade · Score |
|---|---|---|---|---|---|
| 1 | Rosuvastatin / atorvastatin (statins) HMG-CoA reductase inhibitor | 10.0 | 10.0 | 7.0 | S 8.8 |
| 2 | PCSK9 inhibitors (evolocumab / alirocumab / inclisiran) Monoclonal antibody or siRNA | 8.0 | 10.0 | 9.0 | S 8.7 |
| 3 | VO2 max / HIIT Movement | 10.0 | 8.0 | 7.0 | S 8.5 |
| 4 | Ezetimibe NPC1L1 inhibitor | 8.0 | 5.0 | 10.0 | A+ 8.4 |
| 5 | Lp(a)-lowering therapies (olpasiran / pelacarsen / lepodisiran / zerlasiran / muvalaplin) RNA-targeted or small-molecule Lp(a) lowering | 8.0 | 10.0 | 7.0 | A 7.9 |
| 6 | Icosapent ethyl (Vascepa) Purified EPA ester | 8.0 | 8.0 | 7.0 | A- 7.6 |
| 7 | Obicetrapib CETP inhibitor (next-generation) | 8.0 | 8.0 | 7.0 | A- 7.6 |
| 8 | Sauna (Finnish/dry) Thermal | 8.0 | 8.0 | 7.0 | A- 7.6 |
| 9 | Zone 2 cardio Movement | 6.0 | 6.5 | 9.0 | B+ 7.3 |
| 10 | Altitude training / intermittent hypoxia (IHT) Oxygen/Pressure | 8.0 | 5.0 | 7.0 | B+ 7.2 |
| 11 | Retatrutide GLP-1/GIP/glucagon agonist (triple) | 8.0 | 10.0 | 5.0 | B+ 7.1 |
| 12 | Citrus bergamot Polyphenol extract | 6.0 | 5.0 | 9.0 | B+ 7.1 |
| 13 | Time-restricted eating (TRE) Fasting | 6.0 | 5.0 | 9.0 | B+ 7.1 |
| 14 | TUDCA (tauroursodeoxycholic acid) Bile acid / chemical chaperone | 6.0 | 5.0 | 9.0 | B+ 7.1 |
| 15 | Orlistat Lipase inhibitor | 8.0 | 3.5 | 7.0 | B 6.9 |
| 16 | Aspirin (low-dose) Irreversible COX-1 inhibitor | 8.0 | 8.0 | 5.0 | B 6.8 |
| 17 | Cagrilintide Amylin analog | 8.0 | 8.0 | 5.0 | B 6.8 |
| 18 | Maridebart cafraglutide (MariTide) GLP-1 agonist + GIP antagonist | 8.0 | 8.0 | 5.0 | B 6.8 |
| 19 | Mazdutide (IBI362) GLP-1/glucagon agonist (dual) | 8.0 | 8.0 | 5.0 | B 6.8 |
| 20 | Orforglipron Oral GLP-1 agonist (small molecule) | 8.0 | 8.0 | 5.0 | B 6.8 |
| 21 | Semaglutide GLP-1 agonist | 8.0 | 8.0 | 5.0 | B 6.8 |
| 22 | Setmelanotide MC4R agonist | 8.0 | 8.0 | 5.0 | B 6.8 |
| 23 | Survodutide GLP-1/glucagon agonist (dual) | 8.0 | 8.0 | 5.0 | B 6.8 |
| 24 | Tirzepatide GLP-1/GIP agonist (dual) | 8.0 | 8.0 | 5.0 | B 6.8 |
| 25 | Garlic extract (aged / allicin) Organosulfur polyphenol | 6.0 | 3.5 | 9.0 | B 6.8 |
| 26 | Liraglutide GLP-1 agonist | 8.0 | 6.5 | 5.0 | B 6.6 |
| 27 | Contrave (bupropion + naltrexone) Combination | 8.0 | 5.0 | 5.0 | B 6.4 |
| 28 | Dulaglutide GLP-1 agonist | 8.0 | 5.0 | 5.0 | B 6.4 |
| 29 | Berberine AMPK activator / natural | 6.0 | 5.0 | 7.0 | B- 6.3 |
| 30 | Fasting-mimicking diet (FMD / ProLon) Fasting | 6.0 | 5.0 | 7.0 | B- 6.3 |
| 31 | Intermittent fasting (general) Fasting | 6.0 | 5.0 | 7.0 | B- 6.3 |
| 32 | Pramlintide Amylin analog (short-acting) | 8.0 | 3.5 | 5.0 | B- 6.1 |
| 33 | Phentermine Sympathomimetic | 8.0 | 6.5 | 3.5 | B- 6.0 |
| 34 | Bempedoic acid ACL inhibitor | 7.0 | 5.0 | 5.0 | B- 5.9 |
| 35 | Niacin (nicotinic acid) B3 / lipid modifier | 8.0 | 5.0 | 3.5 | B- 5.8 |
| 36 | Topiramate Anticonvulsant | 8.0 | 5.0 | 3.5 | B- 5.8 |
| 37 | Bimagrumab Activin receptor antagonist | 6.0 | 6.5 | 5.0 | C+ 5.7 |
| 38 | FGF21 analogs (efruxifermin / pegozafermin / efimosfermin) FGF21 analog / MASH pipeline | 6.0 | 6.5 | 5.0 | C+ 5.7 |
| 39 | Clenbuterol Beta-2 agonist | 8.0 | 8.0 | 2.0 | C+ 5.6 |
| 40 | Red yeast rice Natural monacolin K source | 6.0 | 5.0 | 5.0 | C+ 5.5 |
| 41 | Naltrexone (low dose, LDN) Opioid antagonist | 3.0 | 2.0 | 9.0 | C+ 5.3 |
| 42 | DNP (2,4-dinitrophenol) Mitochondrial uncoupler | 8.0 | 10.0 | 0.0 | C 5.1 |
| 43 | CLA (conjugated linoleic acid) Fatty acid | 4.5 | 2.0 | 7.0 | C 5.1 |
| 44 | Nattokinase Fibrinolytic enzyme | 3.0 | 5.0 | 7.0 | C 4.9 |
| 45 | Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline) Beta-2 adrenergic agonist | 6.0 | 3.5 | 3.5 | C 4.6 |
| 46 | Extended fasting (24-72h+) Fasting | 4.0 | 5.0 | 5.0 | C 4.6 |
| 47 | Meldonium Carnitine-pathway metabolic modulator | 4.0 | 3.5 | 5.0 | C- 4.3 |
| 48 | Trimetazidine Cardiac metabolic modulator | 3.0 | 3.5 | 5.0 | D+ 3.9 |
| 49 | Tesofensine Triple monoamine reuptake inhibitor | 3.0 | 6.5 | 3.5 | D+ 3.7 |
| 50 | AICAR AMPK activator / exercise mimetic | 2.0 | 8.0 | 3.0 | D 3.3 |
| 51 | Diuretic weight-cutting / masking agents Diuretic / masking agent | 3.0 | 5.0 | 2.0 | D 2.9 |
| 52 | SR9009 / SR9011 REV-ERB agonist / exercise mimetic | 2.0 | 5.0 | 3.0 | D 2.9 |
| 53 | Insulin / insulin-mimetics for performance use Insulin anabolic/metabolic manipulation | 3.0 | 8.0 | 0.0 | D- 2.6 |